Form 4: Alkermes Executive Craig C. Hopkinson Reports Changes in Beneficial Ownership
SEC Form 4 Filing
EVP R&D, Chief Medical Officer of Alkermes, Craig C. Hopkinson, reports transactions involving ordinary shares and restricted stock units.
Summary
- Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- On February 22, 2025, Hopkinson acquired 12,279 ordinary shares through the vesting of restricted stock units and disposed of 5,452 shares to cover tax obligations at a price of $35.32 per share.
- Following these transactions, he directly owned 69,648 ordinary shares.
- On February 23, 2025, Hopkinson acquired 7,689 ordinary shares through the vesting of restricted stock units and disposed of 3,414 shares to cover tax obligations at a price of $35.32 per share.
- Following these transactions, he directly owned 73,923 ordinary shares.
- Hopkinson also holds restricted stock unit awards, some of which are fully vested and others that vest in annual installments.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.
Positives
- The vesting of restricted stock units indicates a form of compensation and alignment of the executive's interests with the company's performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may be interested in the transactions of company executives as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Commencement date for annual vesting installments of some restricted stock unit awards. |
| 02/22/2025 | Date of transaction involving acquisition of 12,279 ordinary shares and disposal of 5,452 ordinary shares. |
| 02/23/2025 | Date of transaction involving acquisition of 7,689 ordinary shares and disposal of 3,414 ordinary shares. |
| 02/25/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.